Use of ATR inhibitor in combination with topoisomerase I inhibitor kills cancer cells by disabling DNA replication initiation and fork elongation

被引:0
|
作者
Josse, R. [1 ]
Martin, S. E. [2 ]
Guha, R. [2 ]
Ormanoglu, P. [2 ]
Pfister, T. [3 ]
Morris, J. [4 ]
Doroshow, J. [4 ]
Pommier, Y. [1 ]
机构
[1] NCI, Dev Therapeut Branch, Bethesda, MD 20892 USA
[2] NCATS, Div Preclin Innovat, Rockville, MD USA
[3] Leidos Biomed Res Inc, Lab Human Toxicol & Pharmacol, Frederick, MD USA
[4] DTP DCTD, Drug Synth & Chem Branch, Bethesda, MD USA
关键词
D O I
10.1016/S0959-8049(14)70374-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
248
引用
收藏
页码:83 / 83
页数:1
相关论文
共 50 条
  • [31] The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells
    Deng, Shiwei
    Yan, Tiandong
    Nikolova, Teodora
    Fuhrmann, Dominik
    Nemecek, Andrea
    Goedtel-Armbrust, Ute
    Kaina, Bernd
    Wojnowski, Leszek
    BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (09) : 2246 - 2257
  • [32] ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
    Yazinski, Stephanie A.
    Comaills, Valentine
    Buisson, Remi
    Genois, Marie-Michelle
    Nguyen, Hai Dang
    Ho, Chu Kwen
    Kwan, Tanya Todorova
    Morris, Robert
    Lauffer, Sam
    Nussenzweig, Andre
    Ramaswamy, Sridhar
    Benes, Cyril H.
    Haber, Daniel A.
    Maheswaran, Shyamala
    Birrer, Michael J.
    Zou, Lee
    GENES & DEVELOPMENT, 2017, 31 (03) : 318 - 332
  • [33] Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells
    Chen, WS
    Liu, JH
    Liu, JM
    Lin, JK
    ANTI-CANCER DRUGS, 2004, 15 (03) : 287 - 294
  • [34] Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).
    Reichert, Zachery R.
    Devitt, Michael Edward
    Alumkal, Joshi J.
    Smith, David C.
    Caram, Megan Veresh
    Palmbos, Philip
    Vaishampayan, Ulka N.
    Alva, Ajjai Shivaram
    Braun, Thomas
    Yentz, Sarah Elizabeth
    Tsao, Phoebe A.
    Dreicer, Robert
    Cackowski, Frank Cameron
    Shah, Neel
    Dean, Emma
    Smith, Simon
    Heath, Elisabeth I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment
    Garikapati, Koteswararao
    Young, In-Chi
    Hong, Sunhwa
    Rai, Priyamvada
    Jain, Chaitanya
    Briegel, Karoline J.
    ONCOGENE, 2024, 43 (12) : 851 - 865
  • [36] Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment
    Koteswararao Garikapati
    In-Chi Young
    Sunhwa Hong
    Priyamvada Rai
    Chaitanya Jain
    Karoline J. Briegel
    Oncogene, 2024, 43 : 851 - 865
  • [37] PROTEIN-LINKED DNA STRAND BREAKS INDUCED IN MAMMALIAN-CELLS BY CAMPTOTHECIN, AN INHIBITOR OF TOPOISOMERASE-I
    COVEY, JM
    JAXEL, C
    KOHN, KW
    POMMIER, Y
    CANCER RESEARCH, 1989, 49 (18) : 5016 - 5022
  • [38] DIFFERENTIATION INDUCTION OF HUMAN PROMYELOCYTIC LEUKEMIA-CELLS BY 10-HYDROXYCAMPTOTHECIN, A DNA TOPOISOMERASE-I INHIBITOR
    LING, YH
    TSENG, MT
    NELSON, JA
    DIFFERENTIATION, 1991, 46 (02) : 135 - 141
  • [39] Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
    Matsuno, Yusuke
    Hyodo, Mai
    Fujimori, Haruka
    Shimizu, Atsuhiro
    Yoshioka, Ken-ichi
    CANCERS, 2018, 10 (10):
  • [40] Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I–DNA complex
    N Sen
    B Banerjee
    B B Das
    A Ganguly
    T Sen
    S Pramanik
    S Mukhopadhyay
    H K Majumder
    Cell Death & Differentiation, 2007, 14 : 358 - 367